



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

**Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts**

Public declaration of interests

I, Günter Karl-Heinz Auerswald

Organisation/Company: EHC (European Haemophilia Consortium)

Country: Germany

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
01/2000-06/2014	Pfizer	Refacto AF, PI of the PUP study	therapy for haemophilia A

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

Period	Company	Products	Therapeutic Indication
07/2014-(current)	Biogen Idec	protocol 997HA306 and 998HB303	treatment of haemophilia A and B, data safety monitoring board

2.6 Investigator

No Interest Declared

2.7 Grant / Funding to organisation /institution

No interest declared

2.8 Close family member interest

No interest declared

2.9 Any other interests or facts

I'm a member of the Zürich Haemophilia Forum. This forum meets on an annual basis where the meeting is organised by Parexel with funding by Novo Nordisk. The outcome of the meeting is reflected in an article which is published in a scientific journal. I received reimbursement of travel and accommodation costs as well as a honorarium from Parexel, but not from NovoNordisk directly. I will intend to continue with participation in this advisory board/forum and refrain from accepting additional honoraria/fees.

Regarding the training courses for physiotherapists paid by Novo Nordisk, I clarify that this training is open to all physiotherapists and not for Physiotherapists invited by the company and I got only reimbursement of reasonable costs from the company. No additional honorarium or fee will be paid.

I attended a meeting of German haemophilia treaters of CCC's for the purpose of developing new guidelines for the therapy of haemophilia patients with inhibitors on the 27th of February 2017. Travel costs were compensated by CSL-Behring, no honorary.

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result

of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Dr. Guenter Auerswald
Date:	2018-05-17

For Definitions of activities etc, refer to Policy on Handling of Conflicts of Interest / Electronic DOI template